About BioCardia

We are a clinical-stage regenerative medicine company.

Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Our Pipeline: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia.

Our second therapeutic candidate is the investigational CardiALLO™  Cell Therapy System, an allogeneic culture expanded "off the shelf" cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. This therapy has the potential to be advanced for many clinical indications including heart failure.



News

28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
16 Apr

Saint Joseph Mercy

St. Joseph Mercy Ann Arbor to perform clinical trial using stem cells to treat congestive heart failure
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More

press releases

14 Jan
2020 BioCardia Announces FDA Clearance of Morph DNA Deflectable Guide Catheter
08 Jan
2020 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery
19 Nov
2019 BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights
28 Oct
2019 BioCardia to Present at Dawson James Securities' 5th Annual Small Cap Growth Conference
08 Oct
2019 BioCardia Receives CE Mark Renewal for Helix Biotherapeutic Delivery Catheter and Morph Guide Catheter Through May 2024
02 Oct
2019 BioCardia Announces the Appointment of Two New Board Members
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS